Vinay Bhaskar, Ph.D.
Dr. Vinay (Vin) Bhaskar brings extensive biotech experience to his current role at MPM where he is responsible for investment identification, due diligence and business development. He also serves as acting Chief Operating Officer for MPM portfolio company Werewolf Therapeutics. Vin is a board member of Werewolf and is a board observer for Naked Biome, all MPM portfolio companies.Prior to joining MPM, Vin led external R&D for the oncology therapeutic area at Amgen, where he was instrumental in forging collaborations with companies such as Kite Pharma, Merck and Xencor. During this time, he also led internal immuno-oncology strategy discussions and served as executive sponsor and/or board observer for several Amgen Ventures investments, including Surface Oncology, Precision BioSciences and Tizona Therapeutics, a company founded by MPM. He joined Amgen through its acquisition of Onyx Pharmaceuticals, where he led preclinical search, evaluation and diligence for licensing and acquisition opportunities on the Asset Acquisition Team. Prior to joining Onyx, Vin held a variety of roles of increasing responsibility in discovery research at Portola Pharmaceuticals, XOMA, PDL Biopharma and Eos Biotechnology. In these roles, he initiated and led multiple preclinical project teams and functional groups focused on biologies that spanned oncology, inflammation and cardiometabolic disease. Through these endeavors, he has gained broad expertise across all phases of drug discovery, early development and process sciences.Vin holds a Ph.D. in Biochemistry from the University of California, Los Angeles and a B.S. in Biochemistry from the University of California, Davis.